Biogen Idec Inc. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
5,860
8,582
9,321
10,194
10,990
12,053
Cost of Goods Sold (COGS) incl. D&A
1,201
1,610
1,623
1,807
2,414
2,198
Gross Income
4,660
6,973
7,698
8,387
8,577
9,855
SG&A Expense
3,241
4,126
4,126
3,921
4,171
4,693
EBIT
1,418
2,847
3,572
4,466
4,406
5,163
Unusual Expense
7
29
143
587
225
476
Non Operating Income/Expense
6
32
142
11
89
55
Interest Expense
32
30
96
260
246
201
Pretax Income
2,481
3,947
4,767
4,933
5,129
5,900
Income Tax
601
990
1,162
1,237
2,459
1,426
Equity in Affiliates
17
15
13
-
-
-
Consolidated Net Income
1,862
2,942
3,593
3,696
2,670
4,474
Net Income
1,862
2,935
3,547
3,703
2,539
4,431
Net Income After Extraordinaries
1,862
2,935
3,547
3,703
2,539
4,431
Net Income Available to Common
1,862
2,935
3,547
3,703
2,539
4,431
EPS (Basic)
7.81
12.37
15.34
16.92
11.92
21.58
Basic Shares Outstanding
237
236
231
218
213
205
EPS (Diluted)
7.81
12.37
15.34
16.92
11.92
21.58
Diluted Shares Outstanding
238
237
231
219
213
205
EBITDA
1,950
3,484
4,172
5,149
5,456
5,813
Non-Operating Interest Income
8
12
22
63
79
113
Minority Interest Expense
-
7
46
7
131
43
Equity in Affiliates (Pretax)
1,085
1,114
1,270
1,239
1,204
1,247

About Biogen Idec

View Profile
Address
225 Binney Street
Cambridge Massachusetts 02142
United States
Employees -
Website http://www.biogen.com
Updated 07/08/2019
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.